These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 9758314

  • 1. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?
    Nawarskas JJ, Spinler SA.
    Pharmacotherapy; 1998; 18(5):1041-52. PubMed ID: 9758314
    [Abstract] [Full Text] [Related]

  • 2. Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction.
    Guazzi MD, Campodonico J, Celeste F, Guazzi M, Santambrogio G, Rossi M, Trabattoni D, Alimento M.
    Clin Pharmacol Ther; 1998 Jan; 63(1):79-86. PubMed ID: 9465844
    [Abstract] [Full Text] [Related]

  • 3. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors.
    van Wijngaarden J, Smit AJ, de Graeff PA, van Gilst WH, van der Broek SA, van Veldhuisen DJ, Lie KI, Wesseling H.
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):240-5. PubMed ID: 7511753
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 6. [The antagonistic effect of aspirin on the expression of prostaglandin participation in the antihypertensive activity of ACE inhibitors].
    Alimento M, Campodonico J, Santambrogio G, Rossi M, Trabattoni D, Celeste F, Guazzi M.
    Cardiologia; 1997 Jun; 42(6):605-10. PubMed ID: 9289376
    [Abstract] [Full Text] [Related]

  • 7. Interaction between cyclooxygenase and the renin-angiotensin-aldosterone system: rationale and clinical relevance.
    Meune C, Mourad JJ, Bergmann JF, Spaulding C.
    J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):149-54. PubMed ID: 14608518
    [Abstract] [Full Text] [Related]

  • 8. Angiotensin-converting enzyme inhibitors and end-organ damage in heart failure.
    Sami M.
    Can J Cardiol; 1999 May; 15 Suppl C():19C-23C. PubMed ID: 10380688
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin converting enzyme inhibitors and the cardiovascular system.
    Dzau VJ.
    J Hypertens Suppl; 1992 Jun; 10(3):S3-10. PubMed ID: 1386105
    [Abstract] [Full Text] [Related]

  • 10. [Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].
    Costantino S, Millozzi F, Scarlata S.
    Clin Ter; 2001 Jun; 152(2):77-8. PubMed ID: 11441526
    [No Abstract] [Full Text] [Related]

  • 11. [Trends in pharmacological treatment of congestive heart failure].
    Halawa B.
    Pol Merkur Lekarski; 1999 Mar; 6(33):152-6. PubMed ID: 10365602
    [Abstract] [Full Text] [Related]

  • 12. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure.
    McAlister FA, Ghali WA, Gong Y, Fang J, Armstrong PW, Tu JV.
    Circulation; 2006 Jun 06; 113(22):2572-8. PubMed ID: 16735672
    [Abstract] [Full Text] [Related]

  • 13. From digoxin to angiotensin-converting enzyme inhibitors: issues in pharmacotherapy for congestive heart failure.
    Hackenbruck HA.
    Clin Excell Nurse Pract; 2000 Jul 06; 4(4):197-204. PubMed ID: 11261079
    [Abstract] [Full Text] [Related]

  • 14. [Aspirin, angiotensin converting enzyme inhibitors and cardiac insufficiency].
    de Groote P, Aumégeat V, Meurice T, Millaire A, Lamblin N, Lablanche JM.
    Arch Mal Coeur Vaiss; 2000 Feb 06; 93(2):167-71. PubMed ID: 10830093
    [Abstract] [Full Text] [Related]

  • 15. Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction: a review of clinical investigations.
    Mancini GB.
    Clin Invest Med; 2000 Apr 06; 23(2):144-61. PubMed ID: 10852664
    [Abstract] [Full Text] [Related]

  • 16. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA, Wendt C, Saborowski F.
    Fiziol Cheloveka; 2005 Apr 06; 31(6):97-105. PubMed ID: 16366159
    [Abstract] [Full Text] [Related]

  • 17. [Angiotensin II AT1 receptor antagonists: clinical development and future perspectives].
    Burnier M, Brunner HR.
    Therapie; 1998 Apr 06; 53(3):279-84. PubMed ID: 9773127
    [Abstract] [Full Text] [Related]

  • 18. Class effects of angiotensin-converting enzyme inhibitors.
    Sica DA.
    Am J Manag Care; 2000 Feb 06; 6(3 Suppl):S85-108; quiz S109-11. PubMed ID: 10977451
    [Abstract] [Full Text] [Related]

  • 19. [ACE inhibitors and their clinical significance].
    Brunner HR, Waeber B, Nussberger J.
    Herz; 1987 Dec 06; 12 Suppl 1():3-9. PubMed ID: 3325394
    [Abstract] [Full Text] [Related]

  • 20. [Angiotensin-converting enzyme inhibition and cardiovascular prevention: more than twenty years of clinical success].
    Borghi C, Cosentino E, De Sanctis D.
    Ital Heart J Suppl; 2005 Dec 06; 6(12):769-79. PubMed ID: 16444921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.